NDAORALTABLET
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
LANOXIN (digoxin) by Pfizer is digoxin's actions are mediated through its effects on na-k atpase. First approved in 1997.
Drug data last refreshed 8m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LANOXIN (digoxin) is a cardiac glycoside administered orally as a tablet that increases myocardial contractility and slows heart rate by inhibiting Na-K ATPase and enhancing parasympathetic tone. It is indicated for heart failure and certain arrhythmias, particularly atrial fibrillation, in patients requiring improved cardiac output and rate control.
LOE Approaching
Product approaches loss of exclusivity with moderate competitive pressure (30/100), signaling potential team contraction and shift from growth-focused roles to lifecycle management.
Mechanism of Action
digoxin's actions are mediated through its effects on Na-K ATPase. This enzyme, the "sodium pump," is responsible for maintaining the intracellular milieu throughout the body by moving sodium ions out of and potassium ions into cells. By inhibiting Na-K ATPase, digoxin causes increased availability…
Pharmacologic Class:
Cardiac Glycoside
Indications
Worked on LANOXIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.